Is CHE a Buy or a Sell? The Bull and Bear Case (2026)
Last updated July 2026
Short answer
Both cases are real, which is why the question is contested. The bull case for CHE (CHE) rests on VITAS hospice demand and aging demographics: An aging US population and rising acceptance of hospice care support steady demand for VITAS services. The bear case rests on vITAS derives the large majority of its revenue from Medicare and Medicaid, so reimbursement rate changes, the annual per-patient Cap, and policy shifts can materially affect results. Analysts covering it publish targets from $436.00 to $510.00 against a $540.25 price, so even the professionals disagree by 16% of their own average. We do not give a verdict. What follows is each case at full strength, so you can decide which set of assumptions you actually believe. Walnut is not an investment adviser.
Chemed Corporation runs two entirely unrelated businesses under one holding company. VITAS Healthcare, roughly two-thirds of revenue, is a leading provider of end-of-life hospice and palliative care, drawing well over 90% of its revenue from Medicare and Medicaid per-diem payments. Roto-Rooter, the remaining third, is the largest US provider of plumbing, drain cleaning, and water-damage restoration, serving both residential and commercial customers through company-owned operations and franchises. The two segments share little operationally but together produce steady consolidated cash flow that management returns via buybacks and a small dividend. The investment picture is one of slow, reliable compounding rather than rapid growth. VITAS benefits from aging demographics and rising hospice utilization but is capped by Medicare per-patient limits and tight regulatory oversight, while Roto-Rooter is more cyclical and weather-sensitive, and has recently seen softer demand and margin pressure in its restoration business. In early 2026 VITAS was the stronger performer (revenue up around 3%) while Roto-Rooter revenue dipped slightly, and management raised full-year adjusted EPS guidance. Investors weigh a defensive, high-return-on-capital model against reimbursement risk, plumbing cyclicality, and a valuation that already reflects the company's quality.
The bull case: what would have to be true for $510.00
The most optimistic published target on CHE is $510.00, -5.6% from the $540.25 price as of July 2026. Getting there needs the following to work close to its best case, not merely to avoid going wrong.
1. VITAS hospice demand and aging demographics
An aging US population and rising acceptance of hospice care support steady demand for VITAS services. VITAS grew net revenue roughly 3% year over year in Q1 2026 to about $420 million, and management has been expanding capacity and admissions. Because hospice is a defensive, non-discretionary service, this segment provides ballast against economic cycles.
2. Reduced Medicare Cap drag
VITAS has periodically faced Medicare Cap billing limitations that force refunds when payments exceed per-patient ceilings. Management projected the Cap headwind to fall sharply to roughly $9.5 million in 2026 from about $27.2 million in 2025, which supports higher realized VITAS revenue and margins if admissions and length-of-stay trends hold.
3. Roto-Rooter footprint and franchise buy-ins
Roto-Rooter is the dominant national brand in plumbing and drain services, giving it pricing power and brand recall competitors lack. Chemed continues to buy back independent franchise territories (adding markets serving millions of people in early 2026), converting franchise royalties into higher-margin company-owned revenue over time.
4. Strong cash generation and buybacks
Chemed converts earnings into substantial free cash flow (roughly $325 million after capex in 2025) with low debt, and consistently repurchases shares. This capital-return discipline steadily shrinks the share count and supports per-share earnings even when consolidated revenue grows only in the mid-single digits.
The bear case: what would have to be true for $436.00
The most pessimistic published target is $436.00, -19.3% from the current price. That is not a floor and not a forecast; it is roughly what one analyst thinks CHE is worth if the risks below bite instead of the drivers above.
VITAS derives the large majority of its revenue from Medicare and Medicaid, so reimbursement rate changes, the annual per-patient Cap, and policy shifts can materially affect results. The hospice industry faces heavy regulatory oversight (Conditions of Participation, anti-kickback and false-claims rules, audits, and past MAC repayment demands), and VITAS disclosed a 2025 cyberattack exposing protected health information. Roto-Rooter is cyclical and weather-dependent, with recent softness in restoration demand and margin pressure, plus reliance on scarce licensed-plumber labor. The stock also trades at a premium multiple, so any disappointment on volumes or margins can drive sharp drawdowns, as seen after weaker quarters.
The bear case deserves the same attention as the bull case, and usually gets less. If you are holding CHE already, the question is not whether these risks exist but whether any of them has moved from possible to actually happening in the reported numbers.
Where analysts land on CHE
4 analysts cover CHE, with an average target of $474.00 (-12.3% against $540.25) and a split of 1 buy, 3 hold, 0 sell. Bear in mind sell-side ratings skew positive across the whole market, so that split is not a balanced vote. The full target table, the recent rating actions by firm, and how the consensus has shifted are on the CHE forecast and price target page.
How is CHE valued? (as of July 2026)
Snapshot for CHE as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
- Revenue (TTM): ~$2.5B
- Net income (FY2025): ~$265M
- Free cash flow (FY2025, after capex): ~$325M
- 2026 adjusted EPS guidance: ~$23.25-$24.25
- Market cap: ~$6B
- P/E ratio: ~20x
Chemed posted 2025 revenue of about $2.53 billion (up ~4%) with net income near $265 million, and Q1 2026 consolidated revenue of roughly $657 million split about $420 million VITAS and $237 million Roto-Rooter. The stock traded near $480 in early July 2026, giving a market cap around $6 billion and a trailing P/E in the low-20s. Management raised full-year 2026 adjusted EPS guidance to roughly $23.25 to $24.25.
How do you decide if CHE is a buy?
Rather than asking whether CHE is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the bull case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold CHE indirectly through an index or sector ETF before adding more.
What would change your mind on CHE
Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.
- Bull case breaks if: VITAS hospice demand and aging demographics stalls in the reported numbers rather than in the narrative around them.
- Bear case breaks if: vITAS derives the large majority of its revenue from Medicare and Medicaid, so reimbursement rate changes, the annual per-patient Cap, and policy shifts can materially affect results fails to materialise over several reporting periods while the drivers keep compounding.
- Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.
For the full picture, see the CHE stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about CHE against your real portfolio and see your actual exposure before deciding.
Investing in CHE with AI
Connect the broker you already use and ask Walnut's AI how CHE fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
Is CHE a good stock to buy right now?
+
That depends on which case you find more convincing, and both are on this page. The bull case rests on VITAS hospice demand and aging demographics, with revenue (ttm) at ~$2.5B. The bear case rests on vITAS derives the large majority of its revenue from Medicare and Medicaid, so reimbursement rate changes, the annual per-patient Cap, and policy shifts can materially affect results. Analysts covering it are spread from $436.00 to $510.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.
Should I sell CHE?
+
Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. VITAS derives the large majority of its revenue from Medicare and Medicaid, so reimbursement rate changes, the annual per-patient Cap, and policy shifts can materially affect results. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $436.00, -19.3% from the $540.25 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.
What is the bull case for CHE?
+
VITAS hospice demand and aging demographics. An aging US population and rising acceptance of hospice care support steady demand for VITAS services. The most optimistic analyst target on CHE is $510.00, -5.6% from the $540.25 price. That figure is only reachable if this thesis works close to its best case.
What is the bear case for CHE?
+
VITAS derives the large majority of its revenue from Medicare and Medicaid, so reimbursement rate changes, the annual per-patient Cap, and policy shifts can materially affect results. The hospice industry faces heavy regulatory oversight (Conditions of Participation, anti-kickback and false-claims rules, audits, and past MAC repayment demands), and VITAS disclosed a 2025 cyberattack exposing protected health information. Roto-Rooter is cyclical and weather-dependent, with recent softness in restoration demand and margin pressure, plus reliance on scarce licensed-plumber labor. The stock also trades at a premium multiple, so any disappointment on volumes or margins can drive sharp drawdowns, as seen after weaker quarters. The most pessimistic published target is $436.00, -19.3% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.
What does CHE do?
+
Chemed Corporation runs two entirely unrelated businesses under one holding company.
What would have to change for CHE to stop being worth holding?
+
Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (VITAS hospice demand and aging demographics) stalling in the reported numbers rather than in the narrative, the risk above (vITAS derives the large majority of its revenue from Medicare and Medicaid, so reimbursement rate changes, the annual per-patient Cap, and policy shifts can materially affect results) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.
What does Chemed Corporation do?
+
Chemed operates two unrelated businesses: VITAS Healthcare, a large US hospice and palliative-care provider, and Roto-Rooter, the biggest North American plumbing, drain-cleaning, and water-restoration brand. VITAS is roughly two-thirds of revenue and Roto-Rooter the remaining third.
How does Chemed make money?
+
VITAS earns per-diem payments, mostly from Medicare and Medicaid, for caring for terminally ill patients. Roto-Rooter earns service fees from residential and commercial plumbing, drain, and restoration jobs plus royalties from independent franchise territories.
Why are hospice and plumbing in the same company?
+
It is a legacy conglomerate structure. The two segments share little operationally but both generate steady cash flow, and Chemed manages them in a decentralized way while allocating the combined cash toward buybacks, franchise acquisitions, and a modest dividend.
Walnut is informational, not investment advice, and gives no verdict on CHE. Analyst targets referenced here come from a July 2026 pull of published third-party research and change constantly. Verify current figures with your broker before acting on them.